Puntrakul C, Kitkumthorn N, Lapthanasupkul P, Landes C, Vorakulpipat C. Osteocalcin and C-terminal telopeptide of type I collagen in serum and saliva: A cross-sectional pilot study on correlations and implications for MRONJ risk stratification in women on antiresorptive medications. J Clin Exp Dent. 2026;18(9):e1130-41.
doi:10.4317/jced.64415
https://doi.org/10.4317/jced.64415
References
|
1. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194(2 Suppl):S3-11. |
|
|
2. Khandelwal S, Lane NE. Osteoporosis: Review of Etiology, Mechanisms, and Approach to Management in the Aging Population. Endocrinol Metab Clin North Am. 2023;52(2):259-75. |
|
|
3. Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK. Osteoporosis: A Review of Treatment Options. P T. 2018;43(2):92-104. |
|
|
4. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022;80(5):920-43. |
|
|
5. Hamada H, Matsuo A, Koizumi T, Satomi T, Chikazu D. A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography. J Craniomaxillofac Surg. 2014;42(6):924-9. |
|
|
6. Bagan JV, Cibrian RM, Lopez J, Leopoldo-Rodado M, Carbonell E, Bagan L, Gavaldá C. Sclerosis in bisphosphonate-related osteonecrosis of the jaws and its correlation with the clinical stages: Study of 43 cases. Br J Oral Maxillofac Surg. 2015;53(3):257-62. |
|
|
7. Hutcheson A, Cheng A, Kunchar R, Stein B, Sambrook P, Goss A. A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: A prospective single-center controlled study. J Oral Maxillofac Surg. 2014;72(8):1456-62. |
|
|
8. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65(12):2397-410. |
|
|
9. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000;66(2):100-3. |
|
|
10. Salgueiro M, Stribos M, Zhang LF, Stevens M, Awad ME, Elsalanty M. Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): A retrospective clinical study. EPMA J. 2019;10(1):21-9. |
|
|
11. Betsy J, Ahmed JM, Mohasin AK, Mohammed A, Nabeeh AA. Diagnostic accuracy of salivary biomarkers of bone turnover in identifying patients with periodontitis in a Saudi Arabian population. J Dent Sci. 2019;14(3):269-76. |
|
|
12. Joseph B, Javali MA, Khader MA, AlQahtani SM, Amanullah M. Salivary Osteocalcin as Potential Diagnostic Marker of Periodontal Bone Destruction among Smokers. Biomolecules. 2020;10(3):380. |
|
|
13. Wongla A, Buranaphatthana W, Tachasuttirut K. Salivary C-terminal Telopeptide Levels in Patients with Medication-related Osteonecrosis of the Jaw. CM Dent J. 2021;42(1):173-83. |
|
|
14. Eastell R, O'Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, Cummings SR. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2(1):16069. |
|
|
15. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone. 2011;48(4):677-92. |
|
|
16. Dempster DW, Lambing CL, Kostenuik PJ, Grauer A. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: A review of preclinical and clinical data. Clin Ther. 2012;34(3):521-36. |
|
|
17. Marx RE. Oral & Intravenous Bisphosphonate-induced Osteonecrosis of the Jaws: History, Etiology, Prevention, and Treatment. Chicago: Quintessence Publishing Company; 2006. |
|
|
18. Gossiel F, Altaher H, Reid DM, Roux C, Felsenberg D, Gluer CC, Eastell R. Bone turnover markers after the menopause: T-score approach. Bone. 2018;111:44-8. |
|
|
19. Park SG, Jeong SU, Lee JH, Ryu SH, Jeong HJ, Sim YJ, Kim GC, Jeong H. The Changes of CTX, DPD, Osteocalcin, and Bone Mineral Density During the Postmenopausal Period. Ann Rehabil Med. 2018;42(3):441-8. |
|
|
20. Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Wang A, Siris E, Cummings SR. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):530-7. |
|
|
21. Ashcherkin N, Patel AA, Algeciras-Schimnich A, Doshi KB. Bone turnover markers to monitor oral bisphosphonate therapy. Cleve Clin J Med. 2023;90(1):26-31. |
|
|
22. Greenblatt MB, Tsai JN, Wein MN. Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. Clin Chem. 2017;63(2):464-74. |
|
|
23. Kwon YD, Kim DY, Ohe JY, Yoo JY, Walter C. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(12):2644-8. |
|
|
24. Nassif A, Lignon G, Asselin A, Zadikian CC, Petit S, Sun HW, Gorin C, Sadoine J. Transcriptional Regulation of Jaw Osteoblasts: Development to Pathology. J Dent Res. 2022;101(7):859-69. |
|
|
25. Gong X, Yu W, Zhao H, Su J, Sheng Q. Skeletal Site-specific Effects of Zoledronate on in vivo Bone Remodeling and in vitro BMSCs Osteogenic Activity. Sci Rep. 2017;7(1):36129. |
|
|
26. Kuroshima S, Al-Omari FA, Sasaki M, Sawase T. Medication-related osteonecrosis of the jaw: A literature review and update. Genesis. 2022;60(8-9):e23500. |
|
|
27. Tetradis S, Allen MR, Ruggiero SL. Pathophysiology of Medication-Related Osteonecrosis of the Jaw-A Minireview. JBMR Plus. 2023;7(8):e10785. |
|
|
28. Jagtap VR, Ganu JV, Nagane NS. BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women. Indian J Clin Biochem. 2011;26(1):70-3. |
|
|
29. Kerschan-Schindl K, Boschitsch E, Marculescu R, Gruber R, Pietschmann P. Bone turnover markers in serum but not in saliva correlate with bone mineral density. Sci Rep. 2020;10(1):11550. |
|
|
30. Peisker A, Raschke GF, Fahmy MD, Guentsch A, Roshanghias K, König KC, Schultze-Mosgau S. Cross-Sectional Study of four Serological Bone Turnover Markers for the Risk Assessment of Medication-Related Osteonecrosis of the Jaw. J Craniofac Surg. 2018;29(2):e137-40. |
|